Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy

Helicobacter
Chao-Hung KuoDeng-Chyang Wu

Abstract

The prospective study was designed to clarify the impact of CYP2C19 on quadruple therapies and survey the efficacies of rabeprazole-based quadruple therapy for Helicobacter pylori infection after failure of standard triple therapies. From January 2007 to March 2009, 1055 H. pylori-infected patients received standard triple regimens (proton-pump inhibitor (PPI), clarithromycin, and amoxicillin). Helicobacter pylori eradication was achieved in 865 (81.9%) subjects. One hundred ninety eradication-failure patients were enrolled and randomly assigned to receive a 7-day eradication therapy. Ninety-six patients were treated with esomeprazole-based quadruple rescue therapies (EB), while 94 patients were treated with rabeprazole-based quadruple rescue therapies (RB). Follow-up endoscopy was done 16 weeks later to assess the treatment response. Patients' responses, CYP2C19 genotypes, and antibiotics resistances were also examined. Intention-to-treat analysis revealed that RB had better eradication rates than EB (EB: 72.9%; 95% CI: 64.9-80.9% and RB: 78.7%; 95% CI 72.5-84.9%) (p value = .543). Per-protocol results were EB = 75.3%; 95% CI: 70.3-80.3% and RB = 85.1%; 95% CI: 80.6-89.6% (p value = .0401). Both regimens had similar compliance...Continue Reading

References

Aug 1, 1995·Biological & Pharmaceutical Bulletin·M TsuchiyaK Kobashi
May 1, 1997·The Journal of Antimicrobial Chemotherapy·N FiguraM Dattilo
Sep 5, 1997·The Journal of Biological Chemistry·M BesanconJ M Shin
Jul 27, 1999·Archives of Internal Medicine·M B FennertyM Helfand
Sep 24, 1999·Alimentary Pharmacology & Therapeutics·M P Williams, R E Pounder
Sep 1, 2000·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M HeepN Lehn
Nov 1, 2001·Alimentary Pharmacology & Therapeutics·Y HoraiT Ishizaki
Feb 28, 2002·Alimentary Pharmacology & Therapeutics·P MalfertheinerUNKNOWN European Helicobacter Pylori Study Group (EHPSG)
Jul 30, 2002·Alimentary Pharmacology & Therapeutics·P Della MonicaA Pera
Oct 3, 2002·The American Journal of Gastroenterology·Ping I HsuYoshio Yamaoka
Mar 5, 2003·Alimentary Pharmacology & Therapeutics·J Dent
Oct 11, 2003·Alimentary Pharmacology & Therapeutics·H LamouliatteUNKNOWN Multicentre Study Group
Jun 29, 2004·Journal of Clinical Gastroenterology·George K AnagnostopoulosDimitrios Arvanitidis
Jul 13, 2004·Basic & Clinical Pharmacology & Toxicology·Ulrich KlotzGerhard Treiber
Jul 1, 2005·Drug Metabolism and Pharmacokinetics·Takahisa FurutaTakashi Ishizaki
Sep 24, 2005·Helicobacter·Peter Bytzer, Colm O'Morain
Aug 19, 2006·Expert Opinion on Investigational Drugs·Andrea MorgnerStephan Miehlke
Aug 1, 2007·Journal of Clinical Gastroenterology·George SachsKeith Munson

❮ Previous
Next ❯

Citations

Jun 20, 2014·World Journal of Gastroenterology : WJG·Kyu Keun KangHyun Chae Jung
Mar 25, 2014·The Kaohsiung Journal of Medical Sciences·Tzung-Shiun WuChao-Hung Kuo
Aug 30, 2012·Expert Review of Gastroenterology & Hepatology·Silvia Marelli, Fabio Pace
Jul 14, 2012·Gastroenterology Research and Practice·Chao-Hung KuoDeng-Chyang Wu
Aug 2, 2011·The American Journal of the Medical Sciences·Tsung-Hui HuMing-Luen Hu
Jun 20, 2015·BioMed Research International·Guang-Hong JhengPing-I Hsu
Apr 1, 2017·Clinical Drug Investigation·Leon Fisher, Alexander Fisher
Apr 14, 2015·Terapevticheskiĭ arkhiv·Yu V Evsyutina, A S Trukhmanov
Jan 23, 2016·World Journal of Clinical Cases·Maliheh SafaviAlireza Foroumadi
Dec 5, 2014·World Journal of Gastroenterology : WJG·Chao-Hung KuoFu-Chen Kuo
Jan 21, 2021·Gut and Liver·Hye-Kyung JungUNKNOWN Korean College of Helicobacter and Upper Gastrointestinal Research
Jun 8, 2021·The Korean Journal of Internal Medicine·Hye-Kyung JungUNKNOWN Korean College of Helicobacter and Upper Gastrointesinal Research

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.